Cannabis Science Inc  

(Public, OTCMKTS:CBIS)   Watch this stock  
Find more results for PINK:CBIS
0.0740
0.0000 (0.00%)
Delayed:   3:26PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.07 - 0.08
52 week 0.03 - 0.30
Open 0.07
Vol / Avg. 1.29M/3.21M
Mkt cap 62.64M
P/E     -
Div/yield     -
EPS -0.01
Shares 846.42M
Beta 2.01
Inst. own 0%
Jun 4, 2014
Q1 2014 Cannabis Science Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -565752.40% -7189.60%
Operating margin -515382.50% -6870.12%
EBITD margin - -3942.48%
Return on average assets -2018.01% -704.41%
Return on average equity - -
Employees 5 -
CDP Score - -

Address

Suite B #254, 6946 North Academy Blvd
COLORADO SPRINGS, CO 80918
United States - Map
+1-888-8890888 (Phone)

Description

Cannabis Science, Inc. is a development-stage company. Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The Company is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

Officers and directors

Dorothy Bray Ph.D. Chairperson of the Board, President, Chief Executive Officer
Chad S. Johnson Esq. General Legal Counsel, Corporate Secretary, Director
Age: 45
Mario Lap Director